Bunse, Lukas 1988-
Lukas Bunse
VIAF ID: 308741751 (Personal)
Permalink: http://viaf.org/viaf/308741751
Preferred Forms
-
100 1 _ ‡a Bunse, Lukas ‡d 1988-
-
100 0 _ ‡a Lukas Bunse
4xx's: Alternate Name Forms (2)
5xx's: Related Names (5)
- 551 _ _
‡a
Heidelberg
‡4
ortw
‡4
https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _
‡a
Klinikum Heidelberg
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Neurologische Klinik
‡g
Mannheim
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Neurologische Universitätsklinik
‡g
Heidelberg
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 551 _ _
‡a
Villingen-Schwenningen
‡4
ortg
‡4
https://d-nb.info/standards/elementset/gnd#placeOfBirth
Works
Title | Sources |
---|---|
Actively personalized vaccination trial for newly diagnosed glioblastoma |
![]() |
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. |
![]() |
Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes |
![]() |
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
![]() |
High-throughput discovery of cancer-targeting TCRs |
![]() |
Intrathecal activation of CD8<sup>+</sup> memory T cells in IgG4-related disease of the brain parenchyma |
![]() |
K27M-mutant histone-3 as a novel target for glioma immunotherapy |
![]() |
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy |
![]() |
Nivolumab for Treatment of Progressive Multifocal Leukoencephalopathy in Sézary Syndrome |
![]() |
Phenotype and modulation of T cell responses in isocitrate dehydrogenase 1 mutant gliomas |
![]() |
pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients |
![]() |
The promises of immunotherapy in gliomas. |
![]() |
Proximity ligation assay evaluates IDH1R132H presentation in gliomas |
![]() |
Spontane Immunantworten gegen mutierte Isozitratdehydrogenase 1 in Gliompatienten |
![]() |
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate |
![]() |
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway |
![]() |
TCR validation toward gene therapy for cancer |
![]() |
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas |
![]() |
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor |
![]() |
A vaccine targeting mutant IDH1 induces antitumour immunity. |
![]() |